1 Clinical Trials associated with SAR-442257 NCT04401020 / Active, not recruitingPhase 1 An Open-label, First-in-human, Single Agent, Dose Escalation Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442257 in Patients With Relapsed and Refractory ...
In conclusion, SAR442257 has high potential for enhancing TC cytotoxicity by co-targeting CD38 and CD28 on MM and CD3/CD28 on T cells. Keywords: T cell engager; cell avidity; refractory multiple myeloma; microenvironment1. Introduction Multiple myeloma (MM) is a hematological cancer characterized ...